$4.11
12.30% yesterday
Nasdaq, Sep 03, 10:15 pm CET
ISIN
US75943R1023
Symbol
RLAY

Relay Therapeutics Inc Stock price

$4.11
+0.46 12.60% 1M
+0.91 28.44% 6M
-0.01 0.24% YTD
-2.36 36.48% 1Y
-20.92 83.58% 3Y
-32.82 88.87% 5Y
-30.94 88.27% 10Y
-30.94 88.27% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.45 12.30%
ISIN
US75943R1023
Symbol
RLAY
Industry

Key metrics

Basic
Market capitalization
$631.0m
Enterprise Value
$-25.8m
Net debt
positive
Cash
$656.8m
Shares outstanding
171.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
75.5 | 47.9
EV/Sales
negative | negative
EV/FCF
0.1
P/B
1.0
Financial Health
Equity Ratio
89.3%
Return on Equity
-43.4%
ROCE
-49.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$8.4m | $13.2m
EBITDA
$-338.2m | $-361.1m
EBIT
$-343.1m | $-358.0m
Net Income
$-311.6m | $-293.4m
Free Cash Flow
$-262.1m
Growth (TTM | estimate)
Revenue
-86.2% | 31.5%
EBITDA
46.5% | 1.6%
EBIT
46.2% | 3.9%
Net Income
46.4% | 13.1%
Free Cash Flow
7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,046.8% | -2,743.2%
EBIT
-4,105.6%
Net
-3,728.5% | -2,228.4%
Free Cash Flow
-3,136.2%
More
EPS
$-1.8
FCF per Share
$-1.5
Short interest
16.0%
Employees
197
Rev per Employee
$50.0k
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8.36 8.36
86% 86%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 69 69
48% 48%
826%
- Research and Development Expense 292 292
50% 50%
3,491%
-338 -338
47% 47%
-4,045%
- Depreciation and Amortization 4.91 4.91
11% 11%
59%
EBIT (Operating Income) EBIT -343 -343
46% 46%
-4,104%
Net Profit -312 -312
46% 46%
-3,727%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
Neutral
The Motley Fool
27 days ago
Relay (RLAY) Q2 Loss Narrows 41%
Neutral
GlobeNewsWire
27 days ago
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RL...
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 197
Founded 2015
Website relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today